PPARgamma represents a key target for the treatment of type 2 diabetes and metabolic syndrome. Synthetic antidiabetic drugs activating PPARgamma are accompanied by serious undesirable side effects related to their agonism. In the search for new PPARgamma regulators, inhibitors of PPARgamma phosphorylation on S245 mediated by CDK5 represent an opportunity for the development of an improved generation of antidiabetic drugs acting through this nuclear receptor. We have employed a multidisciplinary approach, including protein-protein docking, X-ray crystallography, NMR, HDX, MD simulations, and site-directed mutagenesis to investigate conformational changes in PPARgamma that impair the ability of CDK5 to interact with PPARgamma and hence inhibit PPARgamma phosphorylation. Finally, we describe an alternative inhibition mechanism adopted by a ligand bound far from the phosphorylation site.

Insights into PPARgamma Phosphorylation and Its Inhibition Mechanism

Montanari R;Capelli D;Pirone L;Pedone E;Pochetti G
2020

Abstract

PPARgamma represents a key target for the treatment of type 2 diabetes and metabolic syndrome. Synthetic antidiabetic drugs activating PPARgamma are accompanied by serious undesirable side effects related to their agonism. In the search for new PPARgamma regulators, inhibitors of PPARgamma phosphorylation on S245 mediated by CDK5 represent an opportunity for the development of an improved generation of antidiabetic drugs acting through this nuclear receptor. We have employed a multidisciplinary approach, including protein-protein docking, X-ray crystallography, NMR, HDX, MD simulations, and site-directed mutagenesis to investigate conformational changes in PPARgamma that impair the ability of CDK5 to interact with PPARgamma and hence inhibit PPARgamma phosphorylation. Finally, we describe an alternative inhibition mechanism adopted by a ligand bound far from the phosphorylation site.
2020
Istituto di Biostrutture e Bioimmagini - IBB - Sede Napoli
Istituto di Cristallografia - IC
phosphorylation
PPARgamma
File in questo prodotto:
File Dimensione Formato  
Montanari R Journal of Medicinal Chemistry 2020.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 4.94 MB
Formato Adobe PDF
4.94 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/383159
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 22
social impact